Protagonist Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.61 billion
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- $26.58 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Protagonist Therapeutics Inc had its IPO on 2016-08-11 under the ticker symbol PTGX.
The company operates in the Healthcare sector and Biotechnology industry. Protagonist Therapeutics Inc has a staff strength of 103 employees.
Shares of Protagonist Therapeutics Inc opened at $27.58 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $27.27 - $28.26, and closed at $28.2.
This is a +2.58% increase from the previous day's closing price.
A total volume of 725,400 shares were traded at the close of the day’s session.
In the last one week, shares of Protagonist Therapeutics Inc have increased by +12.26%.
Protagonist Therapeutics Inc's Key Ratios
Protagonist Therapeutics Inc has a market cap of $1.61 billion, indicating a price to book ratio of 1.9246 and a price to sales ratio of 13.2717.
In the last 12-months Protagonist Therapeutics Inc’s revenue was $859000 with a gross profit of $26.58 million and an EBITDA of $-145250000. The EBITDA ratio measures Protagonist Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Protagonist Therapeutics Inc’s operating margin was -17029.45% while its return on assets stood at -31.09% with a return of equity of -54.13%.
In Q1, Protagonist Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Protagonist Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protagonist Therapeutics Inc’s profitability.
Protagonist Therapeutics Inc stock is trading at a EV to sales ratio of 5.843 and a EV to EBITDA ratio of -1.6038. Its price to sales ratio in the trailing 12-months stood at 13.2717.
Protagonist Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $239.86 million
- Total Liabilities
- $23.23 million
- Operating Cash Flow
- $9.83 million
- Capital Expenditure
- Dividend Payout Ratio
Protagonist Therapeutics Inc ended 2023 with $239.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $239.86 million while shareholder equity stood at $-570480000.00.
Protagonist Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $23.23 million in other current liabilities, 1000.00 in common stock, $-570480000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $127.69 million and cash and short-term investments were $230.76 million. The company’s total short-term debt was $2,599,000 while long-term debt stood at $0.
Protagonist Therapeutics Inc’s total current assets stands at $235.74 million while long-term investments were $0 and short-term investments were $103.07 million. Its net receivables were $51000.00 compared to accounts payable of $4.02 million and inventory worth $0.
In 2023, Protagonist Therapeutics Inc's operating cash flow was $9.83 million while its capital expenditure stood at $10000.
Comparatively, Protagonist Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Protagonist Therapeutics Inc stock is currently trading at $28.2 per share. It touched a 52-week high of $28.259 and a 52-week low of $28.259. Analysts tracking the stock have a 12-month average target price of $34.4.
Its 50-day moving average was $23.32 and 200-day moving average was $14.35 The short ratio stood at 3.96 indicating a short percent outstanding of 0%.
Around 167.4% of the company’s stock are held by insiders while 10409.5% are held by institutions.
Frequently Asked Questions About Protagonist Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.